Search engine for discovering works of Art, research articles, and books related to Art and Culture
ShareThis
Javascript must be enabled to continue!

Evolutionary dynamics of neoantigens in growing tumours

View through CrossRef
ABSTRACT Cancer evolution is driven by the acquisition of somatic mutations that provide cells with a beneficial phenotype in a changing microenvironment. However, mutations that give rise to neoantigens, novel cancer–specific peptides that elicit an immune response, are likely to be disadvantageous. Here we show how the clonal structure and immunogenotype of growing tumours is shaped by negative selection in response to neoantigenic mutations. We construct a mathematical model of neoantigen evolution in a growing tumour, and verify the model using genomic sequencing data. The model predicts that, in the absence of active immune escape mechanisms, tumours either evolve clonal neoantigens (antigen– ‘hot’), or have no clonally– expanded neoantigens at all (antigen– ‘cold’), whereas antigen– ‘warm’ tumours (with high frequency subclonal neoantigens) form only following the evolution of immune evasion. Counterintuitively, strong negative selection for neoantigens during tumour formation leads to an increased number of antigen– warm or – hot tumours, as a consequence of selective pressure for immune escape. Further, we show that the clone size distribution under negative selection is effectively– neutral, and moreover, that stronger negative selection paradoxically leads to more neutral– like dynamics. Analysis of antigen clone sizes and immune escape in colorectal cancer exome sequencing data confirms these results. Overall, we provide and verify a mathematical framework to understand the evolutionary dynamics and clonality of neoantigens in human cancers that may inform patient– specific immunotherapy decision– making.
Title: Evolutionary dynamics of neoantigens in growing tumours
Description:
ABSTRACT Cancer evolution is driven by the acquisition of somatic mutations that provide cells with a beneficial phenotype in a changing microenvironment.
However, mutations that give rise to neoantigens, novel cancer–specific peptides that elicit an immune response, are likely to be disadvantageous.
Here we show how the clonal structure and immunogenotype of growing tumours is shaped by negative selection in response to neoantigenic mutations.
We construct a mathematical model of neoantigen evolution in a growing tumour, and verify the model using genomic sequencing data.
The model predicts that, in the absence of active immune escape mechanisms, tumours either evolve clonal neoantigens (antigen– ‘hot’), or have no clonally– expanded neoantigens at all (antigen– ‘cold’), whereas antigen– ‘warm’ tumours (with high frequency subclonal neoantigens) form only following the evolution of immune evasion.
Counterintuitively, strong negative selection for neoantigens during tumour formation leads to an increased number of antigen– warm or – hot tumours, as a consequence of selective pressure for immune escape.
Further, we show that the clone size distribution under negative selection is effectively– neutral, and moreover, that stronger negative selection paradoxically leads to more neutral– like dynamics.
Analysis of antigen clone sizes and immune escape in colorectal cancer exome sequencing data confirms these results.
Overall, we provide and verify a mathematical framework to understand the evolutionary dynamics and clonality of neoantigens in human cancers that may inform patient– specific immunotherapy decision– making.

Related Results

Abstract 943: Filtering out self-like neoantigens improves immune response to cancer vaccines
Abstract 943: Filtering out self-like neoantigens improves immune response to cancer vaccines
Abstract Clinical studies have highlighted the potential of precision cancer immunotherapy to effectively control the tumor of patients across cancer indications....
Pulmonary carcinoid tumours
Pulmonary carcinoid tumours
Key pointsPulmonary carcinoid tumours account for 2% of all lung tumours, with an increase in incidence due to more accurate diagnostic techniques.Carcinoid tumours are relatively ...
Abstract 1898: SNAF: Accurate and compatible computational framework for identifying splicing derived neoantigens
Abstract 1898: SNAF: Accurate and compatible computational framework for identifying splicing derived neoantigens
Abstract Patient outcome with immune checkpoint blockade (ICB) therapy relies largely on the presence and detection of tumor neoantigens. Neoantigens can be produced...
Abstract 1803: Newly emerged immunogenic neoantigens enable to break the resistance of immune checkpoint inhibitors
Abstract 1803: Newly emerged immunogenic neoantigens enable to break the resistance of immune checkpoint inhibitors
Abstract Immune checkpoint inhibitors (ICIs) and other cancer immunotherapies resurge T cell responses that target tumor antigens expressed by cancer cells, particul...
dbPepNeo: a manually curated database for human tumor neoantigen peptides
dbPepNeo: a manually curated database for human tumor neoantigen peptides
Abstract Neoantigens can function as actual antigens to facilitate tumor rejection, which play a crucial role in cancer immunology and immunotherapy. Emerging eviden...
neoANT-HILL: an integrated tool for identification of potential neoantigens
neoANT-HILL: an integrated tool for identification of potential neoantigens
Abstract Background Cancer neoantigens have attracted great interest in immunotherapy due to their capacity to elicit antitumoral responses. These molecules arise from som...
neoANT-HILL: an integrated tool for identification of potential neoantigens
neoANT-HILL: an integrated tool for identification of potential neoantigens
Abstract Background Cancer neoantigens have attracted great interest in immunotherapy due to their capacity to elicit antitumoral responses. These molecules arise from soma...
The neoantigen landscape of mycosis fungoides
The neoantigen landscape of mycosis fungoides
Abstract Background Mycosis fungoides (MF), the most common type of cutaneous T-cell lymphoma, has a dismal prognosis in advanc...

Back to Top